CONTENTS
· Welcome
· Faculty
· Scientific Agenda
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel Accommodations
· Organizer

We are pleased to invite you to attend the 4th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice, which will be held 22-24 February 2008, in beautiful and historic Paris, France! The focus of this congress is to provide a forum to review state-of-the-art and present new data on the diagnosis and management of myeloma, lymphoma and related disorders as well as give attendees the opportunity to exchange ideas with world-renowned opinion leaders.

Last year’s congress, held in Athens, Greece, was attended by more than 650 hematologists and oncologists from 65 countries, most of whom are directly involved in patient care. Their highly positive review of the educational content, quality of the speakers, and presentation excellence attests to the overall satisfaction of the attendees and the value of continuing with a comprehensive update on hematologic oncology management.

To complement the exceptional scientific experience this congress brings, Paris offers the perfect setting for enjoyable after-hours relaxation. There are few cities that can compete with the history, charm, arts and dining experiences that Paris has to offer.  We hope you will join us in this beautiful and historic city for a stimulating and enjoyable congress, as this meeting promises to be an exciting, interactive and educational experience for all attendees.

Kenneth C. Anderson, MD, MA
Dana-Farber Cancer Institute
Boston, Massachusetts
United States

Bart Barlogie, MD, PhD
University of Arkansas
Medical Center
Little Rock, Arkansas
United States

Elias Campo, MD
University of Barcelona
Barcelona, Spain

Bruce D. Cheson, MD
Georgetown University Hospital
Washington, DC
United States

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Daphne De Jong, MD, PhD
The Netherlands Cancer Institute
Amsterdam, The Netherlands

Meletios A. Dimopoulos, MD
University of Athens
Athens, Greece

Martin Dreyling, MD, PhD
University Hospital
Grosshadern/Munchen
Munich, Germany

Brunangelo Falini, MD
University of Perugia
Perugia, Italy

Massimo Federico, MD
Universitá di Modena e
Reggio Emilia
Modena, Italy

Francine Foss, MD
Yale Cancer Center
New Haven, Connecticut
United States

Paolo Ghia, MD, PhD
Università Vita-Salute
San Raffaele
Milan, Italy

John M. Goldman, MD
Hammersmith Hospital
Imperial College
School of Medicine
London, United Kingdom

John G. Gribben, MB, ChB, MD, DSc
Barts Hospital
London, United Kingdom

François Guilhot, MD
University Hospital, Poitiers
Poitiers, France

Hans Haaberg, MD
Uppsala University
Uppsala, Sweden

Corinne Haioun, MD
Henri Mondor Hosptial
Créteil, France

Michael J. Hallek, MD
University of Cologne
Cologne, Germany

Jean-Luc Harousseau, MD
University Hospital Hotel-Dieu
Nantes, France

Rudiger Hehlmann, MD, PhD
Klinikum Mannheim der
Universitat Heidelberg Mannheim
Mannheim, Germany

Elias Jabbour, MD
MD Anderson Cancer Center
Houston, Texas
United States

Tim M. Illidge, Md, PhD, FRCR, FRCP
Christie Hospital
Manchester, United Kingdom

Eva Kimby, MD, PhD
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden

Véronique Leblond, MD
Groupe Hospitalier
Pitié Salpêtrière
Paris, France

David G. Maloney, MD, PhD
Fred Hutchinson Cancer
Research Center
Seattle, Washington
United States

Giampaolo Merlini, MD
University of Pavia
Pavia, Italy

Emilio Montserrat, MD
University of Barcelona
Barcelona, Spain

Owen A. O’Connor, MD, PhD
Columbia University
New York, New York
United States

Eduardo Olavarria, MD, PhD
Imperial College
London, United Kingdom

Michael Pfreundschuh, MD, PhD
Saarland University
Homburg, Germany

Guiseppe Saglio, MD
University of Torino
Torino, Italy

Gilles Salles, MD
Universite Claude
Bernard Lyon and Hospices Civls de Lyon
Lyon, France

Jesus F. San Miguel, MD
University Hospital of Salamanca
Salamanca, Spain

Ali T. Taher, MD
American University of Beirut
Medical Center
Beirut, Lebanon

Catherine Thieblemont, MD, PhD
Centre Hospitalier Lyon Sud
Pierre Bénite, France

Anas Younes, MD
M. D. Anderson Cancer Center
Houston, Texas, United States

Pier Luigi Zinzani, MD
University of Bologna
Bologna, Italy

Friday, 22 February 2008

13:00
Welcome and introduction

Session I: Myeloma
Moderator: Kenneth C. Anderson, MD, MA

13:05
Oncogenomics to target myeloma in the bone marrow microenvironment
Kenneth C. Anderson, MD, MA

13:25
Management of newly diagnosed patients
Jesus F. San Miguel, MD

13:45
Options for relapsed/refractory multiple myeloma
Kenneth C. Anderson, MD, MA

14:05
Auto transplant
Jean-Luc Harousseau, MD

14:25
The curability of multiple myeloma
Bart Barlogie, MD, PhD

14:45
The role of VTE prophylaxis
Ali T. Taher, MD

15:05
Panel discussion

15:20
Break

Session II: Indolent Lymphomas and Related Diseases
Moderator: Eva Kimby, MD, PhD

15:40
Amyloidosis
Giampaolo Merlini, MD

16:00
Waldenstrom’s macroglobulinemia
Meletios A. Dimopoulos, MD

16:20
Splenic marginal zone lymphoma
Catherine Thieblemont, MD, PhD

16:40
Optimal therapy in mantle cell lymphoma
Martin Dreyling, MD, PhD

17:00
Panel discussion

17:10
Chair summary

17:15
Adjourn

Saturday, 23 February 2008

Session III: Chronic Lymphocytic Leukemia
Moderator: Véronique Leblond, MD

9:00
New prognostic indicators
Paolo Ghia, MD, PhD

9:20
Richter’s syndrome
Emilio Montserrat, MD

9:40
Clinical trial update: Front-line management of CLL
Michael J. Hallek, MD

10:00
Treatment options for relapsed/refractory CLL
Véronique Leblond, MD

10:20
Novel agents in CLL
John G. Gribben, MB, ChB, MD, DSc

10:40
Panel discussion

10:50
Break

Session IV: Follicular Lymphoma
Moderator: Eva Kimby, MD, PhD

11:10
Biology of follicular lymphoma
Daphne De Jong, MD, PhD

11:30
Approach to the very young patient with aggressive follicular lymphoma
Gilles Salles, MD

11:50
The role of radioimmunotherapy in follicular lymphoma
Tim M. Illidge, Md, PhD, FRCR, FRCP

12:10
Options for relapsed/refractory follicular lymphoma in the rituximab era
Bertrand Coiffier, MD

12:30
Autologous and allogeneic transplantation in relapsing follicular lymphoma
David G. Maloney, MD, PhD

12:50
Panel discussion

13:00
Lunch break

Session V: Aggressive NHL
Moderator: Bertrand Coiffier, MD

14:30
Is there a new standard of care for DLBCL?
Michael Pfreundschuh, MD, PhD

14:50
Novel regimens in molecular targeting of aggressive lymphomas
Anas Younes, MD

15:10
PET as remission criteria
Bruce D. Cheson, MD

15:30
Trial design according to PET responses
Corinne Haioun, MD

15:50
Panel discussion

16:00
Break

Session VI: T Cell Lymphoma
Moderator: Owen A. O’Connor, MD, PhD

16:20
Front-line treatment of T cell lymphoma
Hans Haaberg, MD

16:40
Targeted agents in T cell lymphoma
Owen A. O’Connor, MD, PhD

17:00
Anaplastic large cell lymphoma:
Biology and treatment
Brunangelo Falini, MD

17:20
Angioimmunoblastic lymphadenopathy:
Biology and treatment
Massimo Federico, MD

17:40
Panel discussion

17:50
Adjourn

Sunday, 24 February 2008

Session VII: Cutaneous T Cell Lymphoma
Moderator: Bertrand Coiffier, MD

9:00
Biology and classification of cutaneous T cell lymphoma
Elias Campo, MD

9:20
Treatment of early stage disease
Francine Foss, MD

9:40
Novel agents in the management of refractory CTCL
Pier Luigi Zinzani, MD

10:00
Panel discussion

10:10
Break

Session VIII: SPECIAL SESSION
Chronic Myelogenous Leukemia
Moderator: John M. Goldman, MD

10:40
BCR-ABL: Formation, mechanisms of action of the different TK inhibitors, possible downstream targets for therapy
Giuseppe Saglio, MD

11:00
Imatinib updated: Clinical data, dosage, toxicity, stopping, and pregnancy
François Guilhot, MD

11:20
Monitoring response to therapy: Cytogenetics and PCR, defining response and failure
John M. Goldman, MD

11:40
Imatinib resistance: Classification and mechanisms of resistance
Eduardo Olavarria, MD, PhD

12:00
Next generation tyrosine kinase inhibitors: Initial results and toxicity
Elias Jabbour, MD

12:20
Prospective clinical trials: Future questions (useable endpoints, statistical considerations, survey of German and international phase III studies)
Rudiger Hehlmann, MD, PhD

12:40
Panel discussion

12:50
Adjourn

This Congress is designed for hematologists and oncologists in active clinical practice involved and/or interested in lymphoma, myeloma and related hematological disorders and their management. No specific knowledge other than a basic familiarity with the principles and practice of hematologic oncology is required for successful participation in this activity.

After successfully completion of this course, attendees should be able to:

• Describe the biology, management and current treatment options of myeloma and lymphoma, as well as chronic myelogenous leukemia, in both the front-line and relapsed/refractory settings
  
• Demonstrate thorough knowledge and current clinical understanding of indolent lymphomas and related diseases
  
• Discuss recent advances in prognostic indicators, front-line and relapsed/refractory treatment and novel agents in chronic lymphocytic leukemia
  
• Evaluate chemotherapy, radioimmunotherapy, targeted therapy, and transplantation as treatment options for various stages of follicular lymphoma
  
• Employ current and novel strategies to improve diagnose and treatment outcomes in aggressive non-Hodgkin’s lymphomas
  
• Integrate important advances in the front-line and targeted treatment in T-cell lymphomas, with a focus on anaplastic large cell lymphoma, angioimmunoblastic lymphoma, and cutaneous T-cell lymphoma
• Impact survival outcomes by assimilating the mechanism of action, toxicity, therapeutic response and overcoming of drug resistance with both current and emerging tyrosine kinase inhibitors in chronic myelogenous leukemia
  

Click here to register online.

Regular . . . . . . . . . . . . . . . . . . . €399
Payment received by 13 February 2008

Full/Onsite . . . . . . . . . . . . . . . . . €499
Registered after 13 February 2008

Resident/Student/Nurse . . . . . . . . €199
*proof of eligibility must accompany registration

To Register: You may register online by 13 February 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the Congress. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than 13 February 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: 4th European Congress on Hematologic Malignancies 308. An attendee is not registered until full payment is received.

Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.

NOTE: Registrants that pay with American Express will be charged in the USD equivalent. This is a policy of American Express. More information may be found at www.oanda.com.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than 13 February 2008. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions
are accepted with written notification. No refunds will be made if notice is received
after 13 February 2008.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

Registration Hours
The Registration and Information Desk
will be staffed:
Friday, 22 February 2008 10:00 – 17:30
Saturday, 23 February 2008 08:00 – 18:00
Sunday, 24 February 2008 08:00 – 13:00

Discounted Airfares:
Contact the Congress travel agent, Age of Travel,
for assistance with your travel needs. Age of Travel can also accommodate pre- and post-Congress extensions.

Tel.: +1 (800) 523 4954 or +1 (404) 591 7120
Email: imedex@ageoftravel.com

Paris Marriott Rive Gauche Hotel & Conference Center
17, Boulevard Saint Jacques
Paris France 75014
Tel.: 33 1 4078 7980
Fax: 33 1 4588 4393
www.marriott.com

Discover the beauty of one of the world’s most celebrated cities at the Paris Marriott Rive Gauche Hotel & Conference Center. We’re located on the Left Bank of the Seine River near the Latin Quarter and Saint-Germain-des-Pres, which was once home to many famous artists and writers. The Marriott hotel in Paris is also moments from Montparnasse business district and sightseeing destinations. Recently renovated, all rooms feature luxurious bedding, safes, high-speed Internet access and air-conditioning.

For the convenience of attendees, a limited number of rooms have been reserved until 31 January 2008 at a discounted rate of €225 single or double occupancy, including VAT, and daily buffet breakfast. This rate is not guaranteed outside the Congress dates or after 31 January 2008.

To reserve your room please contact the Paris Marriott Rive Gauche Hotel & Conference Center reservations department at 33 1 4078 7980 or visit the hotel’s website at www.Marriott.com/parst.com. To receive the group rate, callers must identify themselves as being with the 4th European Congress on Hematologic Malignancies group. Internet users must enter the meeting promotional code: y6xy6xa. Reservation requests received after 31 January 2008 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com